Doxorubicin is one of the most widely used chemotherapy drugs in oncology, approved to treat more than a dozen types of cancer in both adults and children. It works by interfering with the machinery cancer cells need to copy their DNA, ultimately killing them. The drug has been a cornerstone of cancer treatment since the 1970s and remains part of standard regimens for breast cancer, lymphomas, leukemias, and several types of solid tumors.
Cancers Treated With Doxorubicin
The FDA-approved list of indications for doxorubicin is unusually broad for a single chemotherapy drug. It is approved for acute lymphoblastic leukemia, acute myeloblastic leukemia, Hodgkin lymphoma, non-Hodgkin lymphoma, metastatic breast cancer, metastatic Wilms’ tumor, metastatic neuroblastoma, metastatic soft tissue sarcoma, metastatic bone sarcomas, metastatic ovarian carcinoma, metastatic bladder carcinoma, metastatic thyroid carcinoma, metastatic gastric carcinoma, and metastatic lung carcinoma. It also has a specific approval as part of combination chemotherapy after surgery for breast cancer that has spread to the lymph nodes.
In children, doxorubicin is a standard component of treatment for leukemia, lymphoma, Wilms’ tumor, neuroblastoma, and various sarcomas. Its versatility across so many cancer types is part of why it remains essential despite its significant side effects.
How It’s Given: Common Drug Combinations
Doxorubicin is almost always given alongside other drugs rather than on its own. Two of the most well-known regimens illustrate how it fits into treatment plans for very different cancers.
For breast cancer, it’s commonly paired with cyclophosphamide in what’s called the AC regimen. For non-Hodgkin lymphoma, it’s part of the four-drug combination known as CHOP: cyclophosphamide, doxorubicin, vincristine, and prednisone. Each drug in these combinations attacks cancer cells through a different mechanism, which improves the odds of a response and reduces the chance the cancer develops resistance to any single agent.
The drug is given intravenously, typically in cycles spaced a few weeks apart. It’s classified as a vesicant, meaning if it leaks out of the vein during infusion, it can cause blisters or tissue damage at the site. Medical teams take specific precautions to prevent this, and if leakage does occur, cold compresses and elevation are applied immediately.
The “Red Devil” Nickname
Patients often hear doxorubicin called the “red devil” before they start treatment. The name comes partly from the drug’s vivid red color, which is visible in the IV bag and can temporarily turn urine reddish-orange for a day or two after infusion. But the nickname also reflects the drug’s reputation for tough side effects: nausea, vomiting, hair loss, mouth sores, and fatigue are common. In clinical trials comparing standard doxorubicin to a newer formulation, 66% of patients on the standard version experienced hair loss, and 53% had nausea.
Despite the name, doxorubicin is one of the most effective chemotherapy drugs ever developed. The side effects are real and can be difficult, but for many cancers it remains the best available option.
Heart Damage: The Most Serious Risk
The side effect that sets doxorubicin apart from most other chemotherapy drugs is its potential to damage the heart muscle, a condition called cardiomyopathy. This risk is cumulative, meaning it increases with each dose you receive over your lifetime. The recommended lifetime cap is 450 to 550 mg/m² of body surface area. For adults over 70, the recommended limit is lower, at 450 mg/m². Above these thresholds, the risk of irreversible heart failure rises sharply.
Because of this risk, heart function monitoring is built into every treatment plan. Before your first dose, you’ll get a baseline heart function test, typically an echocardiogram that measures how well your heart pumps (a value called the ejection fraction). Once your cumulative dose reaches 200 to 250 mg/m², your heart gets rechecked, and then again after every additional 100 mg/m². If your heart’s pumping ability was already below normal before treatment, monitoring happens more frequently.
The monitoring doesn’t stop when treatment ends. Guidelines recommend a heart function check at the completion of therapy and again six months later. If you received a higher total dose (300 mg/m² or more) or developed any signs of heart trouble during treatment, follow-up scans at one year and five years are also recommended. This long tail of monitoring exists because doxorubicin-related heart damage can appear months or even years after the last dose.
The Liposomal Version: Fewer Heart Side Effects
A modified formulation called pegylated liposomal doxorubicin wraps the drug inside tiny fat-coated particles coated with a polymer that helps them evade the immune system. This changes how the drug behaves in your body in meaningful ways. Standard doxorubicin has a half-life of less than 10 minutes in the bloodstream, while the liposomal version circulates for roughly 74 hours. That extended circulation time allows the drug to accumulate more selectively in tumor tissue, reaching concentrations about 10 times higher in the tumor compared to surrounding healthy tissue.
In a phase III trial of over 500 women with metastatic breast cancer, the liposomal version matched the cancer-fighting effectiveness of standard doxorubicin, with nearly identical progression-free survival (6.9 versus 7.8 months). The real difference was in side effects. The risk of heart damage was more than three times higher with standard doxorubicin. Hair loss dropped dramatically: only 20% of patients on the liposomal version experienced it, compared to 66% on standard doxorubicin. Nausea and vomiting were also less common.
The tradeoff is a different set of side effects. Nearly half the patients receiving the liposomal version developed a painful redness and peeling on the palms and soles of the feet, sometimes called hand-foot syndrome. Mouth sores and mucositis were also more frequent. The liposomal formulation is currently approved for ovarian cancer, multiple myeloma, and Kaposi sarcoma, though it’s used off-label in other settings where reducing heart risk is a priority.
Why Doxorubicin Remains a Standard Treatment
Few chemotherapy drugs have the range of doxorubicin. It works across blood cancers and solid tumors, in adults and children, as a first-line treatment and in advanced disease. Newer targeted therapies and immunotherapies have transformed cancer treatment in recent years, but they work for specific cancer types driven by specific mutations. Doxorubicin’s broad effectiveness means it continues to anchor treatment protocols for cancers where those newer options either don’t exist or haven’t proven superior. The development of the liposomal formulation has also extended its usefulness by offering a way to deliver the drug with less collateral damage to the heart and other organs.